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Volume 60, Number 5 Abstracts 1397intra-arterial thrombolysis for thromboembolic lower extremity arterial oc-
clusions between January 2004 and May 2013. All patients were treated
on a standard surgical ward. Endpoints were incidence of bleeding compli-
cations, duration of thrombolysis, angiographic patency rate, 30-day mortal-
ity rate, and amputation-free rate at 6 months.
Results: Of the 171 cases analyzed, 129 cases underwent low-dose
thrombolysis and 42 underwent high-dose thrombolysis. No major bleeding
complications occurred in the low-dose group versus 5% in the high-dose
group (p ¼ .01). The median duration of thrombolysis was 67 hours
(4e304 hours) in the low-dose and 49 hours (2e171 hours) in the high-
dose group (p ¼ .027). Angiographic patency was restored in 67% of the
cases in the low-dose group versus 79% of the high-dose group (p ¼ .17).
The 30-day mortality rates were 1% in the low-dose versus 5% in the
high-dose group (p ¼ .09). However, this higher mortality rate was not
related to bleeding complications. Major amputation-free rates at 6 months
were 81% in the low-dose group and 88% in the high-dose group (p ¼ .22).
Conclusions: Based on this data series, low-dose thrombolysis for
thromboembolic lower extremity arterial occlusions is as effective as high-
dose thrombolysis; however, the risk of major bleeding complications is sub-
stantially lower when using low-dose thrombolysis.
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Objectives: The aim was to perform a review of the efﬁcacy and safety
of new oral anticoagulants (NOAs) in the management of venous thrombo-
embolism (VTE).Methods: This was a systematic review and meta-analysis. On
March 26, 2014, Medline, Embase, and the Cochrane trial register
were searched for randomized controlled trials (RCTs) comparing
the NOAs dabigatran, rivaroxaban, apixaban, and edoxaban with
vitamin K antagonists (VKAs) in VTE treatment and secondary preven-
tion. Two investigators assessed the methodological quality of the
RCTs. The main study outcomes (efﬁcacy, safety and net clinical
beneﬁt) were expressed as risk ratios (RR) with 95% conﬁdence interval
(CI).
Results: Ten RCTs, mostly with low risk of bias, with nearly
38,000 patients, were identiﬁed. In six trials of treatment, NOAs
were equally effective as VKAs in preventing recurrent symptomatic
VTE (RR 0.89, 95% CI 0.75e1.05), but major bleeding occurred
less often (1.08% vs. 1.73% for VKAs, RR 0.63, 95% CI 0.51e0.77),
leading net clinical beneﬁt to favor NOAs (RR 0.79, 95% CI
0.70e0.90). Fatal bleeding occurred less often with NOAs (0.09% vs.
0.18% for VKAs), a difference that approached statistical signiﬁcance
(RR 0.51, 95% CI 0.26e1.01). In three secondary prevention trials,
NOAs reduced VTE recurrence rates to 1.32% (vs. 7.24% with placebo,
RR 0.17, 95% CI 0.12e0.24) and fatal pulmonary embolism (PE)
(including unexplained deaths) to 0.1% (vs. 0.29% for placebo, RR
0.37, 95% CI 0.10e1.38) at the expense of clinically relevant non-ma-
jor bleeding (4.3% vs. 1.8% for placebo, RR 2.32, 95% CI 1.65e3.35),
but not major bleeding. All-cause mortality rate was reduced to 0.41%
with NOAs (vs. 0.86% with placebo, RR 0.38, 95% CI 0.18e0.79). Net
clinical beneﬁt favored NOAs (RR 0.21, 95% CI 0.15e0.29), and NNT
was 18.
Conclusions: Compared to VKAs, NOAs are not only effective in
treating VTE but also safer in terms of bleeding, thereby conferring clinical
beneﬁt. Their safety and efﬁcacy was conﬁrmed further in secondary preven-
tion trials.
